Core Viewpoint - INVO Fertility, Inc. is expanding its telehealth capabilities at the Wisconsin Fertility Institute to enhance access to fertility care for prospective parents, particularly in underserved areas [1][5]. Group 1: Telehealth Expansion - The telehealth platform allows patients to connect with fertility specialists from home, providing personalized assessments and treatment planning through secure virtual consultations [3][4]. - This initiative aims to break down geographic barriers, making expert fertility care more accessible and convenient for individuals and couples [4][5]. Group 2: Service Reach and Accessibility - The expansion is expected to significantly broaden the reach of Wisconsin Fertility Institute, especially for those in rural areas facing challenges in accessing specialized fertility care [5]. - The integration of telehealth with in-clinic procedures is designed to help families navigate the complexities of fertility treatment with greater confidence and ease [5]. Group 3: Company Overview - INVO Fertility focuses on expanding assisted reproductive technology (ART) care through the establishment and operation of fertility clinics, including the innovative INVOcell medical device [7]. - The company operates two INVO Centers and one IVF clinic in the U.S., and continues to distribute its INVOcell technology to third-party clinics [7].

Core Insights - INVO Fertility, Inc. has announced that its Wisconsin Fertility Institute clinic has been recognized as one of America's Best Fertility Clinics for 2025 by Newsweek [1][2] - The ranking was developed in partnership with Statista and evaluated clinics based on criteria set by the CDC [2][5] - The CEO of INVO Fertility expressed pride in the recognition, attributing it to the dedication of the team in providing high-quality fertility care [2] Company Overview - INVO Fertility is focused on expanding access to assisted reproductive technology (ART) through the establishment, acquisition, and operation of fertility clinics [3] - The company operates two INVO Centers and one IVF clinic in the United States, and is engaged in the sale and distribution of its proprietary INVOcell technology [3] - The INVOcell device allows fertilization and early embryo development to occur in vivo, offering a more natural and affordable alternative to traditional IVF [3] Evaluation Criteria - The evaluation for the America's Best Fertility Clinics included quality metrics based on ART indicators published by the CDC [5] - A nationwide online survey was conducted involving reproductive endocrinologists, infertility specialists, and other medical professionals [5] - Accreditation data from various medical organizations and patient satisfaction data from Google reviews were also considered in the evaluation [5]

Core Insights - INVO Fertility, Inc. has announced that its Wisconsin Fertility Institute clinic has been recognized as one of America's Best Fertility Clinics for 2025 by Newsweek [1][2] - The ranking was developed in partnership with Statista and evaluated clinics based on criteria set by the CDC [2][5] - The CEO of INVO Fertility expressed pride in the recognition, attributing it to the dedication of the team in providing high-quality fertility care [2] Company Overview - INVO Fertility is focused on expanding access to assisted reproductive technology (ART) through the establishment, acquisition, and operation of fertility clinics [3] - The company operates two INVO Centers and one IVF clinic in the United States, and is engaged in the sale and distribution of its proprietary INVOcell technology [3] - The INVOcell device allows fertilization and early embryo development to occur in vivo, offering a more natural and affordable alternative to traditional IVF [3] Evaluation Criteria - The evaluation for the Best Fertility Clinics included quality metrics from ART, a nationwide survey of medical professionals, accreditation data from recognized bodies, and patient satisfaction based on Google reviews [5]

Core Insights - NewGen plans to invest US$45 million in the UAE real estate market, focusing on properties near the Wynn Al Marjan Island integrated resort, marking a diversification from its traditional IVF business operations [1][2] - The investment is driven by Ras Al Khaimah's strong economic growth, political stability, and significant infrastructure developments, which are expected to enhance property values [2][5] - NewGen is also considering additional investments in Abu Dhabi's real estate market, which offers stability and long-term growth potential [2][3] Investment Strategy - The company has engaged UAE-based business development manager Samira Aissani to lead property acquisition initiatives, leveraging her extensive experience in UAE real estate [3] - NewGen is in advanced discussions for strategic plot acquisitions in Ras Al Khaimah and has established partnerships with prominent UAE developers [3][4] - A term sheet has been executed with Enclave Capital LLC to raise an additional US$45 million to support the UAE real estate expansion [4] Market Potential - The Wynn Al Marjan Island integrated resort, a multi-billion dollar development set to open in early 2027, is expected to drive demand for real estate in Ras Al Khaimah [2] - The region's strategic location, with 31% of the world's population within four hours' flying time, along with favorable investment policies, creates an ideal environment for real estate appreciation [2] - NewGen's CEO expressed confidence that the investment will deliver substantial returns and establish a strong foundation for future growth [5]

Company Overview - INVO Fertility, Inc. is a healthcare services fertility company focused on expanding access to advanced reproductive treatments through the establishment, acquisition, and operation of fertility clinics and related technologies [4] - The company operates two INVO Centers and one IVF clinic in the United States, and it is engaged in the sale and distribution of its proprietary INVOcell technology to third-party fertility clinics [4] - The INVOcell device allows fertilization and early embryo development to occur in vivo within the woman's body, providing a more natural and affordable experience compared to traditional ART treatments [4] Upcoming Events - INVO Fertility will participate in a webcast fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 [1] - The webcast presentation is scheduled for 4:15 p.m. ET and will be accessible via the conference home page or directly through a provided link [2] - Management will be available for virtual one-on-one meetings throughout the event, with arrangements facilitated through Lytham Partners [3]

Core Insights - NewGenIvf Group Limited has launched First Fertility PGS Center Limited to target the Indian medical tourism market for fertility treatments [1][2] - The global fertility tourism market is projected to grow from US$709 million in 2023 to approximately US$13.08 billion by 2034, with a compound annual growth rate of 30.34% [2] - Thailand is becoming a preferred destination for fertility tourism due to its advanced medical infrastructure, cost-effective treatments, and supportive regulatory environment [2][4] Company Initiatives - First Fertility has developed culturally tailored services for Indian patients, including a dedicated hospitality lounge and Hindi-speaking staff [3] - The center offers comprehensive fertility treatments, including family balance through IVF, which is restricted in India but legally available in Thailand [3] - The initiative aims to create a culturally sensitive environment while providing access to advanced reproductive technologies [3] Market Positioning - Thailand's strategic advantages, such as visa-free entry for Indian nationals and a progressive regulatory environment, support the growth of the medical tourism sector [4] - First Fertility addresses the gap in culturally tailored fertility care for Indian patients, who represent a significant segment of the medical tourism market [4] - The CEO of NewGen emphasized the company's commitment to providing world-class fertility care while capitalizing on market opportunities in Southeast Asia [5]

Core Viewpoint - INVO Fertility is now exclusively focused on the growing fertility market following the divestiture of a majority stake in NAYA Therapeutics, aiming to expand access to advanced fertility treatments and capitalize on supportive policy shifts in the U.S. [1][3] Financial Performance - Revenue for Q1 2025 was $1,637,185, representing a 4% increase from $1,576,286 in Q1 2024 [6] - Consolidated clinic revenue increased by 5% to $1,621,553 compared to $1,537,199 in the previous year [6] - Total revenue from all clinics, including consolidated and equity method clinics, was $1,943,763, up 4% from $1,869,513 [6] - The net loss for the quarter was $(17.4) million, significantly higher than $(1.6) million in the prior year, primarily due to a non-cash impairment charge of $14.6 million related to NAYA Therapeutics [6][11] - Adjusted EBITDA was $(606,551), compared to $(427,467) in the previous year, excluding losses from NAYA TX [6][7] Strategic Focus - The company has sharpened its focus on its core mission as a fertility company, implementing initiatives to accelerate organic clinic growth and exploring acquisitions for expansion [3][4] - The divestiture of NAYA TX is expected to allow both INVO Fertility and NAYA TX to concentrate on their respective opportunities, with INVO Fertility aiming for cash flow break-even and profitability [4][3] Business Model - INVO Fertility is dedicated to expanding assisted reproductive technology (ART) care, focusing on building, acquiring, and operating fertility clinics, including INVO Centers that offer the intravaginal culture (IVC) procedure [8] - The IVC procedure, enabled by the proprietary INVOcell medical device, provides a more natural and affordable experience compared to traditional IVF, with comparable results at a lower cost [8]

Financial Data and Key Metrics Changes - First quarter revenue grew 16.5% to $324 million, primarily due to an increase in the number of clients and covered lives compared to the previous year [15] - Adjusted EBITDA increased by 15% to $58 million, with an adjusted EBITDA margin of 17.8%, slightly down from the previous year [22][28] - Net income was $15.1 million or $0.17 per diluted share, compared to $16.9 million or $0.17 per share in the prior year [22] Business Line Data and Key Metrics Changes - Fertility revenue increased 22% to $206 million, while pharmacy revenue grew 9% to $118 million [20] - ART cycles reached a record high of 16,160, reflecting a 9% growth year-over-year [19] Market Data and Key Metrics Changes - The CDC reported record low birth rates for women aged 25 and younger, while rates for women aged 30 to 44 continue to rise, indicating a shift in family planning trends [6][7] - Over 51% of all births in the U.S. now come from women aged 30 or older, highlighting the increasing need for fertility and maternity solutions [8] Company Strategy and Development Direction - The company is focusing on expanding its product portfolio and enhancing member experience, particularly in women's health and family building [5][9] - New services in maternity, postpartum, and menopause are expected to contribute up to 10% of revenue by 2028, although significant contributions are not anticipated in the near term [13][14] Management's Comments on Operating Environment and Future Outlook - Management raised full-year guidance, projecting revenue between $1.185 billion and $1.235 billion, reflecting growth of 1.5% to 5.8% [27] - The company expects continued member engagement at historical levels, despite potential variability in activity and treatments [25] Other Important Information - The company generated nearly $50 million in operating cash flow in the first quarter, nearly double the prior year period [23] - Total working capital as of March 31 was $331 million, with $256 million in cash and no debt [24] Q&A Session Summary Question: Historical seasonality of cycles per utilizer - Management indicated that guidance reflects uncertainty rather than a change in normal seasonality [30] Question: Drivers of gross margin expansion - Management noted that last year's revenue shortfall affected margins, and while they expect gross margin expansion for the full year, investments may impact margins [31][33] Question: 2026 selling season and RFP process - Management confirmed that they are not seeing a slowdown in RFP activities and are targeting to add at least 1 million new lives each year [38][43] Question: Incremental adjusted EBITDA margin - Management explained that the lower margin is due to investments in platform and product expansion, which are expected to impact the P&L this year [44] Question: Interest in new modules - The menopause product is seeing higher engagement due to a larger addressable audience compared to maternity products [47] Question: Impact of tariffs on costs - Management stated that existing tariffs have not significantly impacted costs, and potential tariffs on pharmaceuticals are not expected to affect their operations [53] Question: Pricing benefits in ART cycles - Management clarified that growth is driven by engagement and activity rather than pricing [68]

Core Insights - NewGen has rebranded its MicroSort technology to NewGenSort, integrating it into its product offerings to enhance reproductive solutions in Asia [1][4] - NewGenSort technology allows for the separation of X and Y chromosome-bearing sperm cells, facilitating family planning and prevention of genetic diseases [2][3] Company Overview - NewGenIvf Group Limited is a comprehensive fertility services provider in Asia, offering a range of fertility treatments to couples and individuals [5] - The company operates clinics in Thailand, Cambodia, and Kyrgyzstan, providing services such as infertility treatments, egg and sperm donation, and surrogacy [5] Technology Applications - NewGen plans to utilize its sperm-sorting technology through two applications: MicroSort for gender selection and MacroSort for addressing male reproductive challenges [3] - MicroSort enables couples to balance family composition, while MacroSort focuses on avoiding sex-linked genetic disorders [3] Strategic Vision - The integration of NewGenSort is seen as a pivotal advancement for the company, expected to accelerate growth and expand market share across Asia [4] - The technology aims to provide personalized reproductive solutions, enhancing the overall family health and prosperity for clients [4]

Core Insights - INVO Fertility, Inc. reported record revenue of $6.5 million for 2024, a 116% increase compared to 2023, driven by the performance of its fertility clinics across the U.S. [4] - The company is refocusing on its core fertility operations following the decision to divest a majority stake in NAYA TX, aiming to capitalize on favorable market trends and increasing public demand for fertility care [4][5] - The U.S. fertility services market is expected to grow due to rising infertility rates and increasing acceptance of assisted reproductive technologies (ART) [7] Q4 2024 Financial Highlights - Revenue for Q4 2024 was $1,685,966, a 22% increase from $1,381,754 in Q4 2023 [6] - Consolidated clinic revenue from the INVO Center in Atlanta and the fertility clinic in Madison increased by 24% to $1,687,300 [6] - Adjusted EBITDA for Q4 2024 was $(450,908), an improvement from $(1.0) million in the prior year [6][14] 2024 Financial Highlights - Total revenue for 2024 reached $6,532,000, up 116% from $3,020,575 in 2023 [6] - Consolidated clinic revenue increased by 125% to $6,450,431 compared to $2,862,574 in 2023 [6] - Net loss for 2024 was $(9.1) million, compared to $(8.0) million in 2023, attributed to the addition of NAYA Therapeutics and merger costs [6] Management Commentary - The CEO highlighted the streamlined operating structure aimed at achieving positive cash flow and the successful expansion into new markets [4] - The company is actively pursuing expansion opportunities in response to declining U.S. fertility rates and rising demand for fertility solutions [4] Market Context - The global fertility services market is projected to grow, driven by rising infertility rates and delayed parenthood [7] - The Centers for Disease Control and Prevention reported a 50% increase in ART-conceived births from 2012 to 2021, with ART now accounting for 2.3% of all births in the U.S. [7]